Rapt Therapeutics (NASDAQ: RAPT)
$7.80
(-1.3%)
-$0.10
Price as of April 25, 2024, 4:00 p.m. ET
Rapt Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Rapt Therapeutics Company Info
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
News & Analysis
Featured Article
Why RAPT Therapeutics Stock Is Crushing It Today
The company reported great results from an early-stage study of its experimental atopic dermatitis drug.
Keith Speights | Jun 14, 2021
Featured Article
These Were the 10 Best IPOs of 2019
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
Taylor Carmichael | Dec 26, 2019
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.